ABBISKO CAYMAN DL-00001 - Asset Resilience Ratio
ABBISKO CAYMAN DL-00001 (8ZD) has an Asset Resilience Ratio of 57.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ABBISKO CAYMAN DL-00001's Asset Resilience Ratio has changed over time. See ABBISKO CAYMAN DL-00001 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down ABBISKO CAYMAN DL-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABBISKO CAYMAN DL-00001 market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.35 Billion | 57.39% |
| Total Liquid Assets | €1.35 Billion | 57.39% |
Asset Resilience Insights
- Very High Liquidity: ABBISKO CAYMAN DL-00001 maintains exceptional liquid asset reserves at 57.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABBISKO CAYMAN DL-00001 Industry Peers by Asset Resilience Ratio
Compare ABBISKO CAYMAN DL-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for ABBISKO CAYMAN DL-00001 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ABBISKO CAYMAN DL-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.39% | €1.35 Billion ≈ $1.58 Billion |
€2.35 Billion ≈ $2.75 Billion |
-21.86pp |
| 2024-12-31 | 79.25% | €1.67 Billion ≈ $1.95 Billion |
€2.11 Billion ≈ $2.46 Billion |
+13.69pp |
| 2023-12-31 | 65.56% | €1.39 Billion ≈ $1.62 Billion |
€2.12 Billion ≈ $2.47 Billion |
-3.16pp |
| 2022-12-31 | 68.72% | €1.71 Billion ≈ $2.00 Billion |
€2.49 Billion ≈ $2.91 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more